Financial Performance Summary

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue: ₹83.13 crore (up 17.3% from ₹70.89 crore)
  • EBITDA: ₹17.95 crore (includes other income) (up 21.9% from ₹14.72 crore)
  • EBITDA Margin: 21.6% (expanded by ~80 bps from 20.8%)
  • PAT: ₹4.86 crore (up significantly from ₹1.21 crore, which included a ₹2.63 crore exceptional item)
  • PAT Margin: 5.85% (vs 1.70%)
  • PBT before exceptional items: ₹6.83 crore (up 39% YoY)
  • Finance Costs: ₹5.84 crore (up 13.4% YoY)

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue: ₹151.94 crore (up 11.6% from ₹136.19 crore)
  • EBITDA: ₹33.13 crore (up 8.4% from ₹30.58 crore)
  • EBITDA Margin: 21.8% (vs 22.4%)
  • PAT: ₹8.17 crore (up 12% from ₹4.71 crore)
  • PAT Margin: 5.38% (vs 3.46%)

Operational Highlights

Revenue Growth Drivers:

  • Achieved through a combination of price increases and sales from new production line
  • Other expenses declined by 4.5% YoY despite 17.3% revenue growth

Capacity Expansion Initiatives:

1. SteriPort Line 3: Commissioned in the first week of September 2026 at existing Kheda facility

  • Increased SteriPort capacity by 75% from 6.6 crore to 11.6 crore bottles
  • Expected to contribute approximately ₹60 crore revenue in FY27
  • Potential annual revenue of ₹110-120 crore at optimal utilization

2. SVP Expansion: Targeted for Q1FY28

  • Will increase capacity from 20.9 crore to 31.7 crore units
  • Will add inhalation, ophthalmic and diluent capacity in highest-margin segment

3. Captive Solar Plant: 10.8 MW capacity operational since end of Q1FY27

  • Expected to save approximately ₹9 crore annually

Management Commentary

Bhavesh Patel, Chairman & Managing Director, commented:

  • Q2FY27 was a strong quarter with revenue growing 17.3% YoY to ₹83.13 crore
  • EBITDA rose 21.9% YoY to ₹17.95 crore with margins expanding to 21.6%
  • PAT stood at ₹4.86 crore with margin of 5.85%
  • The capacity-led growth phase has now begun with SteriPort Line 3 commissioned
  • Confident of building greater scale, enhancing profitability and unlocking sustainable growth opportunities across domestic and export markets

Company Background

Amanta Healthcare Limited is a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products including both large and small volume parenteral (LVPs and SVPs). The company uses advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies to serve six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. Packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml.